Gossamer Bio’s dream run came to a crashing halt this year. The San Diego-based biotech company announced devastating news in February when its flagship drug failed to hit the mark in a major clinical trial, sending shockwaves through the company and its investors. Now, the fallout is real: 77 employees, nearly half the workforce, are getting laid off.

Here’s what went down. Gossamer was testing seralutinib, a drug meant to treat pulmonary arterial hypertension, a serious blood pressure condition that affects the lungs. The Phase 3 study showed promise, the drug actually outperformed the placebo group. But here’s the catch: it didn’t meet the company’s specific statistical targets, even though it cleared the standard scientific threshold. In the cutthroat world of biotech, “close enough” doesn’t cut it for investors.

When investors heard the news, they bolted. Gossamer’s stock value plummeted 78% in a single month, dropping from around $490 million to $105 million by late February. For context, this company was once valued above $1 billion before earlier drug trial disappointments tanked its stock back in 2022. Talk about a rough few years.

CFO Bryan Giraudo explained that the layoffs are all about “conservation of cash” as the company figures out its next move. Most of the cuts are hitting workers on the clinical development and commercial teams, with San Diego and the Bay Area taking the hardest hit. At least the affected workers are getting severance packages, which is something.

CEO Faheem Hasnain tried to put a positive spin on things in February, saying the results “clearly demonstrate seralutinib is an active drug”, even though they fell short of the mark. Now the company is analyzing the data and planning to meet with the FDA to discuss regulatory options and the drug’s future.

Gossamer isn’t totally out of cash yet, the company closed 2025 with about $137 million in reserves, which leadership says is enough to keep the lights on into early next year. But that clock is ticking, and with half the staff gone, it’s clear the company is in survival mode.

This is the reality of biotech: one bad study result can wipe out billions in value and cost hundreds of workers their jobs. It’s a brutal reminder that even with promising research and solid funding, the path from lab to pharmacy shelf is lined with landmines.